BRANFORD, Conn., Sept. 6 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN - News) announced today that Dr. Frank M. Armstrong, President and Chief Executive Officer, will present at the Bear Stearns 19th Annual Healthcare Conference on Tuesday, September 12, 2006, at 4:00 p.m. Eastern time. The conference is being held at The Grand Hyatt New York in New York City on September 11-12, 2006. Dr. Armstrong will provide an update on CuraGen’s advanced oncology pipeline and review the progress being made at 454 Life Sciences, a majority-owned subsidiary of CuraGen.
Access to a live webcast of the presentation will be available from the Investor Relations section of CuraGen’s website at http://www.curagen.com. A replay of the webcast will be available after the presentation and archived for 30 days thereafter.
About CuraGen
CuraGen Corporation (Nasdaq: CRGN - News) is a biopharmaceutical company developing diverse approaches, including novel protein, antibody, and small molecule therapeutics, that aim to offer hope for patients with cancer, inflammatory diseases, and diabetes. CuraGen’s strategic alliances have resulted in a deep pipeline of potential therapeutics that is being developed by the Company’s experienced research and development teams. By leveraging the drug development strengths cultivated over the years, CuraGen expects to make a difference in the lives of patients by bringing forward promising therapeutics that address unmet medical needs. To further capitalize on CuraGen’s extensive research and development expertise, CuraGen founded a majority-owned subsidiary, 454 Life Sciences, which has developed and is commercializing advanced technologies for the sequencing of DNA. CuraGen and 454 Life Sciences are headquartered in Branford, Connecticut. For additional information on the companies please visit http://www.curagen.com and http://www.454.com.
CuraGen Contact: Glenn Schulman, Pharm.D. Assistant Director of Investor Relations gschulman@curagen.com (888) 436-6642
-------------------------------------------------------------------------------- Source: CuraGen Corporation
